Since AD patients are commonly treated with cholinesterase inhibitors, which exert symptomatic effects and some delaying of disease progression, we ought to evaluate a potential interference of AChEI treatment on blood DCs frequency. This evidence concerns the gene BCHE and Alzheimer disease.